TELO (Telomir Pharmaceuticals Inc) Net Profit

Corporate emblem and logo of telomirpharma.com (TELO)

Telomir Pharmaceuticals operates in the speculative longevity niche, where the primary struggle centers on patents. The search for anti-aging molecules is automated using AI and robotics. The company's net profit level on the GURU.Markets chart recorded the metric at -0.05. Meanwhile, the mission to extend human life attracts the world's leading telomere experts to its staff.

TELO (Telomir Pharmaceuticals, Inc.) Company Net Income history from 02/21/2024 to 11/01/2026

Financial and market metric breakdowns for Telomir Pharmaceuticals, Inc. (TELO)

- price and consensus price forecast:
Stock Quotes Telomir Pharmaceuticals Corp|TELO - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Telomir Pharmaceuticals Corp|TELO - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Telomir Pharmaceuticals|TELO - Company Book Value|Market-to-Book Ratio telomirpharma.com|TELO - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Telomir Pharmaceuticals|TELO - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Telomir Pharmaceuticals Inc|TELO - Company Aggregate Debts|Debts to Book Value Telomir Pharmaceuticals Corp|TELO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Telomir Pharmaceuticals|Intermediate Liquidity Ratio telomirpharma.com
- net income and valuation multiples indicators:
TELO - Net Profit
Fundamental valuation:TELO Telomir Pharmaceuticals Corp
Flagship merchandise of Telomir Pharmaceuticals Inc

Geopolitical fragmentation and the disruption of raw material supply chains are hindering the clinical trials of Telomir Pharmaceuticals (TELO), directly impacting operational returns. By analyzing the company's net marginal profit, an investor assesses the daily value generation per unit of capital, where an upward trend confirms business efficiency, while a sharp divergence between revenues and cash flows signals hidden liquidity risks.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Theravance Biopharma, Inc. - Net Income|Profit After Payment of Taxes AQST (Aquestive Therapeutics Inc)|scPharma - Net Profit|Company Net Income Tectonic Therapeutic, Inc.|Tonix Pharmaceuticals (TNXP) - Company Net Income|SXTC (China SXT Pharmaceuticals, Inc.) - Company Net Income|Company Net Income Eupraxia Pharmaceuticals, Inc.|Company Net Income BioHarvest Sciences, Inc. BHST|Company Net Income Invizyne Technologies, Inc. (EXOZ)|Net Income oramed.com ORMP|Net Profit ENTX (Entera Bio)|Net Financial Result ipatherapeutics.com (HYFT)|ABVC - Company Net Income|Final Profit CPIX (Cumberland Pharmaceuticals Inc)|QNTM (Quantum BioPharma Limited) - Net Income|FibroGen Corporation - Final Profit|Company Net Income Rani Therapeutics Holdings|Synergy CHC Corporation - Profit After Tax|Net Profit RLYB|LEXX (lexariabioscience.com) - Final Profit|Net Profit PULM (Pulmatrix Corp)|Net Profit Pheton Holdings Limited PTHL|APM - Company Net Income|Final Profit LYRA (lyratherapeutics.com)|Impact BioMedical Inc (IBO) - Company Net Income|Net Income TNF Pharmaceuticals, Inc.|YCBD (cbdMD Inc.) - Net Profit|Net Profit PainReform Corp|Net Profit CYTO|Net Income lipella.com LIPO|Net Profit OPTN (OptiNose)|Pieris Pharmaceuticals Inc (PIRS) - Company Net Income|PROC: Net Income|PTPI - Net Profit|QLI (Qilian International) - Net Income|SLRN: Profit After Payment of Taxes|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit